Temporary Cessation of DMARD Therapy and COVID-19 Supplemental Dose Vaccine Immunogenicity in Patients With Inflammatory Arthritis

This randomized clinical trial found that, among patients with inflammatory arthritis, holding select biologic or JAKi therapies for 2 weeks at the time of supplemental COVID-19 vaccine dose did not significantly enhance humoral immunogenicity and was associated with transient but clinically meaningful disease flare. Routine interruption of these therapies at the time of COVID-19 dose administration is likely not warranted.

Corresponding Author: Jeffrey R. Curtis, MD, MS, MPH, University of Alabama at Birmingham, 1825 University Blvd, Shelby 172E, Birmingham, AL 35233 (jrcurtis@uabmc.edu).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.